Abstract:Flecainide is a class 1c antiarrhythmic used in the treatment of tachyrhythmias such as paroxysmal supraventricular tachycardia, Wolf-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia, atrial fibrillation, and atrial flutter. Flecainide toxicity can present as milder symptoms such as nausea or vomiting to more severe symptoms such as syncope, coma, dysrhythmias, or even cardiac arrest. Mortality can be as high as 22.5% in severe cases and the half-life of flecainide is 20.5 hours. A 68 year old female with history of longstanding persistent atrial fibrillation on apixaban, hypertension, hyperlipidemia, NASH, and depression, with prior ejection fraction (EF) of 55% who presented to the emergency department after becoming unresponsive when with family. She went into cardiac arrest twice en route with successful resuscitation. In the emergency room, found to be alert but fatigued and normotensive with heart rate in the 60s. First EKG showed QRS 116ms and QTc 509ms. Notably, she had an outpatient cardioversion 10 days prior for her atrial fibrillation for which she was she was started on flecainide the night before the procedure. She was admitted to the cardiac intensive care unit with a lidocaine drip, bicarbonate drip, and intralipid therapy. Due to continued ventricular tachyarrhythmias and continued cardiac arrests despite overdrive pacing leading to refractory cardiogenic shock requiring sedation and vasopressors, she was started on extracorporeal membrane oxygenation (ECMO) support with an impella device for left ventricle unloading. Her ejection fraction was 5-9% on admission with improvement to 40-44% after 5 days of medical management and mechanical support. She had a coronary CT angiogram a month before her cardioversion with a calcium score of 0. Flecainide level came back at 1.59 (0.2-1.0 ug/mL). ICU course was complicated by acute limb ischemia of the impella cannulation limb requiring a bedside SFA perfusion catheter placement as well as a ventilator-associated pneumonia. She had an implantable cardioverter-defibrillator placed for secondary prevention given her probable history of long QT. Flecainide toxicity, although a known phenomenon, is rare. This is a severe case of toxicity in someone who has a likely existing long QT that is either congenital or secondary to her sertraline. Her QTc before and after outpatient cardioversion were 526ms and 530ms respectively. It was thought that flecainide being proarrhythmogenic exacerbated an already prolonged QT. This case highlights the importance of knowing when to get consultation for ECMO support. Veno-arterial ECMO was used here to help cardiopulmonary support in the setting of a likely drug induced and reversible ventricular electrical storm causing severe cardiomyopathy. ECMO in this case gave support through an acute period allowing elimination of flecainide to occur. In addition, this case highlights possible complications of cannulated devices as well as a reminder that underlying conditions can exacerbate the already known adverse effects of a medication.

Safety of flecainide

Flecainide acetate for the treatment of atrial and ventricular arrhythmias

Flecainide in clinical practice

Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation

Oral flecainide therapy and myocardial pacing: preliminary data from a prospective multicenter registry

Mechanism Of Flecainide Antiarrhythmic Action In Experimental Atrial-Fibrillation

Flecainide Toxicity On An Existing Long QT Requiring Mechanical Circulatory Support

Flecainide toxicity-Clinical diagnosis and management of an urgent condition

Flecainide Toxicity From Clinical Pharmacology Perspectives

Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial

Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs

The Effect of Flecainide on the Cardiac Contractility and Electrical Activity in Rabbit Left Ventricle

Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation

Flecainide to Prevent Atrial Arrhythmia after Patent Foramen Ovale Closure, the AFLOAT Study: A Randomized Clinical Trial

The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: Effects on cardiac function and drug clearance

Flecainide toxicity with pill-in-pocket approach from accidental overdose: a case report

Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits

Flecainide induces a sustained countercurrent dependent effect on RyR2 in permeabilized WT ventricular myocytes but not in intact cells

[Therapy and prevention of atrial fibrillation]

Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function

Kir2.1 mutations differentially increase the risk of flecainide proarrhythmia in Andersen Tawil Syndrome